Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Intravenously Administered Dexmedetomidine Versus Clonidine Versus No Alpha-2 Agonist on Emergence Delirium, PACU Length of Stay, and Time to Hospital Discharge in Children Undergoing (Adeno)Tonsillectomy: A Prospective Observational Study

NCT07913308 is registered in ClinicalTrials.gov with Universitair Ziekenhuis Brussel as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07913308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Intravenously Administered Dexmedetomidine Versus Clonidine Versus No Alpha-2 Agonist on Emergence Delirium, PACU Length of Stay, and Time to Hospital Discharge in Children Undergoing (Adeno)Tonsillectomy: A Prospective Observational Study
Lead sponsor
Universitair Ziekenhuis Brussel
Phase
Observational
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
May 31, 2027
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenotonsillectomy, emergency delirium, length of stay, pediatric anesthesia complications, post anesthesia care unit length of stay, postoperative delirium (pod), postoperative pain, tonsillectomy

Arms

As registered; 3 arms.

  • Dexmedetomidine Group Intravenous dexmedetomidine

    Pediatric patients undergoing elective (adeno)tonsillectomy with or without placement of myringotomy tubes who receive intraoperative intravenous dexmedetomidine as part of standard anesthetic care, at the discretion of the attending anesthesiologist.

  • Clonidine Group Intravenous clonidine

    Pediatric patients undergoing elective (adeno)tonsillectomy with or without placement of myringotomy tubes who receive intraoperative intravenous clonidine as part of standard anesthetic care, at the discretion of the attending anesthesiologist.

  • Control Group (No Alpha-2 Agonist) Standard Anesthetic Care Without Alpha-2 Agonist

    Pediatric patients undergoing elective (adeno)tonsillectomy with or without placement of myringotomy tubes who do not receive any intraoperative alpha-2 adrenergic agonist (dexmedetomidine or clonidine) as part of standard anesthetic care.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Incidence and Severity of Emergence Delirium (ED) Assessed at PACU arrival (T0), and at 15 (T15), 30 (T30), 45 (T45), and 60 (T60) minutes post-operatively until PACU discharge.

    Emergence delirium will be assessed using the Pediatric Anesthesia Emergence Delirium (PAED) scale. The PAED scale consists of 5 items, with total scores ranging from 0 to 20, where higher scores indicate greater severity of delirium. A PAED score \>= 10 (or \>= 12) is defined as the presence of emergence delirium.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • CLONIDINE 9 Orange Book patentsPatent cliff August 22, 2045 (Orange Book patent)
    • US 12551466; expires August 22, 2045; assignee not stated
    • US 12233049; expires July 15, 2042; assignee Slayback Pharma LLC
    • US 12440474; expires July 15, 2042; assignee Azurity Pharmaceuticals
    • US 12721837; expires July 15, 2042; assignee not stated
    • US 11918689; expires July 28, 2041; assignee Tris Pharma (United States)
    • +4 more patents
  • DEXMEDETOMIDINE 23 Orange Book patentsPatent cliff January 12, 2043 (Orange Book patent)
    • US 11806334; expires January 12, 2043; assignee BioXcel Therapeutics, Inc.
    • US 11998528; expires January 12, 2043; assignee BioXcel Therapeutics, Inc.
    • US 12090140; expires January 12, 2043; assignee BioXcel Therapeutics, Inc.
    • US 12138247; expires January 12, 2043; assignee BioXcel Therapeutics, Inc.
    • US 12364683; expires January 12, 2043; assignee BioXcel Therapeutics, Inc.
    • +18 more patents

Lead sponsor's other trials

Universitair Ziekenhuis Brussel, most recent start first.

Similar trials

Same condition (Emergence Delirium) and phase, most recent start first.